Limited coverage drugs – tobramycin
Last updated on October 18, 2022
|
Generic name |
Strength / form / brand name | |
|
tobramycin solution (for inhalation) |
300 mg; 5 mL - TOBI® | |
| tobramycin inhalation (powder) | 28 mg capsule, for use with – TOBI® Podhaler® only | |
|
Special Authority criteria |
Approval period |
|---|---|
|
For the cyclic treatment of chronic pulmonary Pseudomonas aeruginosa infections in patients with moderate to severe cystic fibrosis AND who do not tolerate injectable forms of tobramycin to manage inhalation issues. |
Indefinite |
Practitioner exemptions
- None
Special notes
- Cyclic treatment is measured in 28-day cycles and is defined as 28 days "on" tobramycin followed by 28 days "off."
- Tobramycin may be prescribed either as monotherapy or as a combination treatment with another therapy chosen by the prescribing physician.
- Tobramycin is a PharmaCare high-cost drug. PharmaCare reimburses high-cost drugs eligible for coverage to a maximum price based on the manufacturer list price plus a 5% mark-up.